Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016).
Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence.
Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Sci. Pharm. 2009, 77(Short Lectures (SL)), 194; https://doi.org/10.3797/scipharm.oephg.21.SL-27 (registering DOI)
Reverse Chemical Proteomics in Drug Discovery
Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, NSW, 2109 Australia
Author to whom correspondence should be addressed.
Received: 16 April 2009 / Accepted: 16 April 2009 / Published: 16 April 2009
PDF [200 KB, uploaded 12 May 2017]
Abstract With advances in separation technology and structure elucidation, the main bottleneck limiting drug development from natural products is the identification of their cellular targets. Although effective therapeutic agents can be developed and successfully administered without knowledge of the underlying mechanism of action, elucidation of drug target proteins is essential in the design of new compounds with improved safety and efficacy .[...]
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
GOTSBACHER, M.; KARUSO, P. Reverse Chemical Proteomics in Drug Discovery. Sci. Pharm. 2009, 77, 194.
GOTSBACHER M, KARUSO P. Reverse Chemical Proteomics in Drug Discovery. Scientia Pharmaceutica. 2009; 77(Short Lectures (SL)):194.
GOTSBACHER, M.; KARUSO, P. 2009. "Reverse Chemical Proteomics in Drug Discovery." Sci. Pharm. 77, Short Lectures (SL): 194.
Show more citation formats
Show less citations formats
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.